Fletcher and Deming invest in a company seeking to treat and prevent age-related diseases.
Prime Movers Lab’s Suzanne Fletcher and Laura Deming’s Longevity Fund invest in a company seeking to treat and prevent multi age-related diseases. Prime Movers Lab led Elevian, Inc.’s $15 million financing, which in addition to Longevity Fund included Bold Capital Partners, For Good Ventures, Kizoo Ventures, Lauder Partners, SAVEarth Fund and WTI.
Based in Allston, Mass., Elevian is focused on developing medicines that restore youthful regenerative capacity. It will use the capital to advance recombinant GDF11 toward the clinic to treat stroke and other age-related diseases. The company’s scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that replenishing GDF11 – a circulating factor – can regenerate the heart, brain, muscle and other tissues.
In a statement, Suzanne called recombinant GDF11 a “novel therapy and approach to treating stroke and other age-related diseases” and that Elevian “has assembled a team of excellent leaders to develop this multi-disease therapy.”
In conjunction with the financing, Suzanne joined Elevian’s board. Suzanne and firm founder Dakin Sloss are Prime Movers’ two general partners. Suzanne joined the Jackson, Wyo.-based firm last year after leaving her role overseeing the Stanford-StartX Fund.
A deep-tech focused venture firm, Prime Movers closed its debut fund earlier this year at approximately $100 million.
Earlier this year, a Longevity Fund portfolio company, Metacrine, Inc., went public.